2026.10.08 | GP | Healthcare | LUX Infusion: Specialty Infusion Growth

Primary:

LUX Infusion

Associated:

Ivx Health Holdings, Inc.

Soleo Health, Inc.

Total Infusion Care Llc

Biomatrix Specialty Pharmacy, LLC

Viewpoint:

Competitor

Moderator: Jeylan Mammadova (JM)

Colleen Alsop (CA), Former Territory Sales Manager - Option Care Health

SUMMARY

Overview

An industry expert with extensive home infusion, nursing, sales, and operational experience assessed a regional infusion provider’s competitive position. The discussion covered ambulatory infusion centers, home infusion partnerships, payer access, therapy mix, geographic expansion, and profitability.

The provider primarily competes through rapid patient onboarding, strong authorization capabilities, attractive infusion facilities, and expertise in biologics, biosimilars, and immunoglobulin therapies. Its principal challenges are limited home-nursing density and insufficient exposure to acute therapies.

Key Insights

The expert viewed authorization speed and operational flexibility as major advantages over a large national competitor. Greater market density was described as the most important growth requirement. A hub-and-spoke network could connect infusion centers with local home-health nursing partners. Home infusion partnerships currently represent little volume but could grow significantly if reimbursement rules become more favorable. Diversifying into anti-infectives and parenteral nutrition could improve center utilization and strengthen relationships with hospital discharge teams. Transplant and bleeding-disorder services are credible niche opportunities, but success requires coordinated medication delivery, specialized clinical pathways, and nursing coverage beyond metropolitan treatment centers. The provider’s payer panel was considered strong. Demonstrating savings versus hospital-based infusion could support preferred-provider arrangements and patient steering. The expert emphasized that high chair utilization and nurse productivity are essential to protecting center-level profitability.

Competitive Landscape

10/12/2026 at 06:03 AM UTC

Participant type

Positioning

Advantages

Limitations

Target infusion provider

Biologics, biosimilars, and chronic infusion

Fast authorizations, appealing centers, operational flexibility, strong payer access

Limited home-nursing density and acute-care presence

Large national infusion provider

Broad home-infusion platform

Scale, established nursing operations, broad market recognition

Slower processes and occasional difficulty placing patients in centers

Hospital outpatient departments

Traditional infusion setting

Clinical infrastructure and referral access

Significantly higher costs and lower patient convenience

Home-health partners

Contract nursing support

Extend geographic reach without fixed nursing infrastructure

Lower nurse productivity for lengthy home infusions

Quantitative Insights

Metric

Expert assessment

Prior authorization timing

Generally completed within 5–7 days

Nursing payment

Approximately $140–$200 per visit

Partnership-related infusion revenue

Approximately $1,700–$3,500, depending on therapy

Home-partnership share of volume

Typical partnered nursing utilization

Below 5%

3–5 visits

Preferred visit count for attractive economics

Four or fewer

Ambulatory nurse capacity

9–12 patients daily

Home nurse capacity

3–5 patients daily for shorter treatments

Long infusion duration

Approximately 3–6 hours

Ambulatory-site savings versus hospitals

Approximately $3,500–$5,000 per infusion

Hospital infusion cost

Approximately $5,500–$12,000

New regional clinics discussed

Approximately six

Recommended patient travel radius

No more than one hour

Target center utilization

80% scheduled and 70% realized

Historical therapy concentration benchmark

No individual therapy exceeded roughly 4% of gross profit

10/12/2026 at 06:03 AM UTC

JM: Hi, Colleen, can you hear me?

CA: Hello? I can.

JM: Perfect. Thank you so much. Well, hi everyone. This is Jeylan Mammadova and I'm an analyst here at Guidepoint Insights. Today's call will focus on LUX Infusion and we have with us today Colleen Alsop, the former Territory Sales Manager for Option Care Health. Before we start today's conference call, Colleen, could you please begin with an overview of your professional background and then maybe relaying your knowledge and acquaintance around our target company today for LUX Infusion? Okay.

CA: Absolutely. So I have been in the home infusion post-acute space for a couple of decades now, specifically with Option Care Infusion. For over 14 years on sales and sales operations side, spending time. My background is in nursing. I have my master's in nursing and in business. I grew with them from starting out as a rep with them, but then moving all the way up to a regional position, providing sales and training as well as operational support and infrastructure. I currently am the Senior Vice President of Sales for a private equity-owned home health and hospice company, mostly in the Midwest. LUX Infusion, I have worked with them as a competitor when I was at Option Care Infusion. They owned an operation in one of my markets and today, we're ancillary support for them for subrogated nursing on the home health side.

JM: Perfect. Thank you so much. Maybe just starting off, in the specific markets where you directly compete with them, how does LUX position itself against Option Care, direct peers, and just hospital outpatient departments, in which maybe 2 or 3 factors most often determine who wins the referral and how does LUX perform against those different parameters.

CA: In the markets that I worked with them in, they really positioned themselves as the biosimilar and blood therapy market provider. Their time for turnaround in my market was phenomenal. They actually beat us in most spaces for authorizations and getting patients onboarded in those markets as well. And then there are outpatient infusion suites, and those outpatient infusion suites were always very nice, not as clinical as some of the Option Care ones were, and much more desirable for folks who were coming in for those monthly infusions.

JM: When you say that they had a really great turnaround time, what is the difference if you can quantify that versus what you've seen from others?

CA: Sure. Their ability to verbally accept or decline a patient, they were able to do that very quickly and their authorization was generally under 5 to 7 days for prior auth. Sometimes in the larger scale, I know we struggled with that at Option Care, getting the authorizations back timely and being able to get patients onboarded for their initial round of therapy.

JM: What do you think enables that quicker turnaround?

CA: If I had to guess, I would say the ability to be nimble. Their size was not the size of Option Care and they were much more nimble when it came to obtaining the authorization and it just wasn't as large of a corporate structure.

JM: That's super helpful. And maybe which referring specialties present LUX with the clearest opportunity in your view? Would it be more neurology, immunology, and whatnot? And where is its proposition the weakest today?

CA: Their largest opportunity is in the IV. I'm going to take that back. I mean, their margin mix, you know, if they're going to protect your margin, you've got to have a good balance of the IVIGs, the biologics, and the acute therapies. An IVIG and biologic, the biologic heavy mix is where their market is and needs to be. They're very good in that biosimilar market. They do need to, in my opinion, balance that with some acute therapies in order to protect the

10/12/2026 at 06:03 AM UTC

margin just a little bit on some of these drugs. And then really looking for deliberate outpatient hospital diversion to their own infusion suites, you know, and protecting some of that as well. The cost of doing those types of things in the hospital and in physician offices is significantly higher than doing them in an ambulatory infusion suite or even at home, and so being a good hospital diversion plan for your payer markets and then being able to leverage that space.

JM: Just on that point, in offering both home infusion and ambulatory infusion centers, are there specific therapies or patient types that... that flexibility materially maybe improves their chance of winning a referral or for which does maybe a competitor's nursing reach or payer access matter more?

CA: For ambulatory infusion suites and home infusion, those are 2 very different types of patients, you know, the home infusion patient, and this is where LUX struggles probably just a little bit because their density inside markets and being able to provide that large-scale home infusion piece, which is why we're partnered with them, quite honestly, to be able to help provide some of that density. That is the geriatric patient. That is the patient who makes it difficult. That is in places and spaces where it is not nice to come out, you know, weekly, every day, once a month for their therapies, being able to provide that. So 65 and over, or anybody with any kind of acute issue. I lost my train of thought. What makes this desirable from a payer perspective, if you're looking for your inter-payer contracts, if you can increase your density in a market, provide cost savings when you're issuing these therapies. And we're talking about IVIG, any type of MS medication, any type of GI medication. Those are the medications that are recurring chronic meds that people are getting on a monthly basis. If you can share and express cost savings by being able to do these in the home or in an ambulatory infusion suite, not only does it improve your payer contracting, but it also improves your margin as you move forward. But the key is density and the key is being able to, one of the things I took a look at when you think about LUX Infusion is the fact that they have flags posted in lots of places, but really starting to look at a hub-and-spoke type of model where you are increasing the density of your patient population within 1 hour of a place you've already got a flag planted so that you can then increase your scope and breadth that way and synergize some of your costs.

JM: Got it. And maybe if you could speak a little bit more to the partnership with LUX, is that typical in the industry and what are the parameters in that in terms of? Is there a direct referral of patients to LUX centers and like under which conditions, and do they have several partnerships with different versions of Option Care?

CA: So LUX doesn't partner with Option Care. LUX partners with home health companies. So I'm currently in the home health sector. LUX partners with home care companies to help provide them that scalable nursing footprint in the home that they maybe are not able to have. Thank you. With the shop that they currently have open. So they will provide the, LUX will provide the drug, LUX will provide all of the supplies. And then they subrogate the nursing costs to a Medicare-certified home health company to provide the nursing services, lab draws, and all of the things that go along with it. So it is an accessory to the care that LUX is providing, being able to provide that larger footprint for home infusion without having the cost or having to get somebody into their AIC.

JM: Got it. That's really helpful. How is that revenue split structured? Do they receive a fixed fee per infusion or is there a negotiated rate per patient?

CA: There is a negotiated rate per patient, and usually what they do is it's anywhere from $140 to $200 a visit that's paid to the home health company to be able to go out and provide those nursing visits, and LUX determines the number of visits that occur. And it's actually a great partnership to have. I'm sure that... and they have, they should have multiple partnerships. We did Option Care as well, where you, even your own nursing can't get out to go see everybody all of the time. And so you partner with local home care companies to be able to provide you the ancillary nursing.

10/12/2026 at 06:03 AM UTC

JM: Got it. And what would be understanding that maybe not the specific numbers, but just maybe the typical range for revenue per infusion for LUX under these partnerships versus maybe patients that are acquired directly?

CA: Anywhere from $1,700 to $3,500 is what I would say the cost would be. And so, depending on the drug, that's where your revenue kicks in. If you're doing it, it would make sense for them to do this on something like an IVIG, which is 3 days and then once a month or once every couple of months going forward. It does not make sense usually to do this from LUX's perspective, most likely on an IV antibiotic or something that is much more daily every other day, acute just because the margin is just not as high on the drug aspect.

JM: Are those partnership economics, are those negotiated independently by each market, or is there a standard kind of nationally? Just trying to understand how much variation there would be in reimbursement across the different markets.

CA: This is done at the corporate level at LUX. We get a LUX contract to be able to sign and it is negotiated. It is variable, I'm sure, by a couple of $20 to $30, but there's not a huge variability in what the cost would be. Your variability is going to come in the therapy that is assigned or the choice that is made to assign home care to a therapy.

JM: Got it. If you had to maybe fathom and guess what percentage do you think of their total infusion volume comes from these home infusion partnerships today?

CA: Oh, very little. I would say under 5%.

JM: And do you see that staying the same or do you see that percentage growing?

CA: I see that percentage growing if the Medicare rules shift any on home infusion, I could see that shifting drastically.

JM: Do they earn any margin on specialty drugs or is the economics entirely driven by the infusion administration and then the facility fees?

CA: It's by the infusion administration facility fees.

JM: Got it. And what would you say maybe the average utilization rate of their infusion shares today, just trying to understand maybe how much incremental utilization comes from the home infusion partnerships?

CA: So are you asking when a home infusion is in place with a partner, how many nursing visits are done? Is that what you're asking as far as utilization goes?

JM: Yes.

CA: Yeah, usually 3 to 5 visits.

JM: Is there a specific maybe utilization level where a LUX Infusion Center break evens and at what level would it be considered to generate attractive EBITDA margins?

CA: To get attractive EBITDA, you would want your visits to be 4 or less.

JM: And is there a volume threshold where the incremental patient growth would require additional staffing, maybe reducing margin expansion?

CA: Of course, typically, you want your... the ability to see a number of patients per day. If somebody's in an AIC, a nurse can see 9 to 12 patients a day. A home care patient, a home care nurse can maybe see 3 to 5 if it's not a long

10/12/2026 at 06:03 AM UTC

infusion. So if you're talking like an IVIG patient, a home... this is why they send them to home infusion because those are 3 to 4 hour, 3 to 6 hour visits. And so that nurse is tied up with one patient all day long, whereas if that patient is in an outpatient or ambulatory care infusion center, that patient can sit and they can see 9 to 12 patients at a time. So it's a delicate balance of what therapies are you going to put out and let's say at home, occupy a nurse and pay for that nurse to be in that space.

JM: Perfect. That's super helpful. And maybe just on your earlier point around payers, how important are those payer contracts and the specialty pharma network inclusion to convert referrals into starts? And maybe have you observed areas where LUX gains or loses a case because of an access constraint rather than service quality.

CA: Actually, LUX has a really great payer panel when it comes to home infusion. The payer landscape piece for home infusion really is in your acquisition costs and your contracts, your personal contracts to be able to get the right kind of margin on the drug from the get-up. Having the payer contracts is great and being able to take them, but then having the ability to bill what that looks like and then really showing your savings per infusion versus somebody getting those infusions inside of a hospital and being able to leverage that. When you take a look at it, you're really looking at saving anywhere from $3,500 to $5,000 just by having that person in your AIC versus when they send them out to the hospital. It's $5,500 to $12,000 for that same infusion. So leveraging your cost savings as an AIC provider and then getting those improved contracts to be able to increase your own margin and EBITDA at the end. Are you there?

JM: How much volume, yes, apologies, I was speaking to you. How much volume maybe could plausibly be influenced by payer arrangements versus individual prescriber choice, like in the markets that you know, what would a payer need to see to steer significant volume towards LUX?

CA: You need to A, demonstrate your cost savings and B, find a drug or a medication where you can do a hospital diversion program for them with that cost savings and becoming that key provider in those types of things. Find an IVIG drug or an MS drug that you want to build a specific care path around and then being able to divert those patients to the outpatient or your ambulatory infusion centers or to home, those are the ways to leverage a specific population of people, especially in a metro area, and that's something that's very desirable by a payer. It also helps with patient satisfaction. So patients are much more satisfied. We know this. It's published. Patients are much more satisfied getting care inside of their home or inside of an ambulatory infusion suite as opposed to going to the hospital to get these types of therapies. And so, again, that from a referral source standpoint, that is also something that is very desirable.

JM: Got it. That's super helpful. And maybe to your earlier point around the mix right now in biosimilars and that they're very heavy, biologics heavy therapy mix and there needs to be a balance with acute therapies.

CA: Mm-hmm.

JM: Can you explain maybe the underlying economics and maybe if there's specific acute therapies that would be more attractive from a margin perspective that they should try to bring into that mix and how maybe margins differ across branded versus biosim and acute therapies?

CA: Well, in diversifying your mix, you're doing a couple of things. You are inadvertently also making yourself much more relevant in that hospital discharge planner referral source space where typically if you are just a chronic IVIG biologic provider, you are not going to be as known or as popular. And so when you do this, when you diversify your channels, you make a deliberate step into the acute space. So that's your anti-infectives and your TPNs. And I would do this for margin, but not just for margin, but to also help then introduce the fact that you're also here for all of those other therapies, the biosimilars, the people, you know, the IVIG, and you can even cross-use and keep your seats full with short-term IV antibiotic patients, you know, patients who maybe don't have the right environment at home to get

10/12/2026 at 06:03 AM UTC

an infusion or don't have a willing and able caregiver, somebody who doesn't want to be homebound, who works still and can come into your suite to get their labs and their dressing changes, this opens up, it keeps your seats full from a utilization standpoint, it makes yourself much more palatable in that hospital diversion hospital discharge planning model. The margin on those types of things, the anti-infectives and the margin on TPN is actually really good and it needs to be a portion of your therapy mix. I mean, at Option Care, no therapy was over a 4% gross profit. So when looking at maintaining the mix and keeping yourself, again, it's about market density, expanding and growing where you've planted to be able to be on the tips of everybody's tongue for all of the infusion therapies.

JM: Are there specific acute therapies that you would highlight that would be particularly important to their margin strategy? Maybe any limitations as to why they have not been able to expand that acute therapy volume?

CA: I think there's been really good national players in the markets that I've experienced with LUX where they understandably haven't put their pinky toe into what's going on but if they're looking to increase their density then that's the stuff that they need to take. I don't think it needs to be their main flag but probably the answer shouldn't be no we can't do that. As opposed to looking at therapies that we would want to do or not do, I would look at patient types because you're looking for ambulatory patients, patients who work. Those are patients that are difficult to place at a national provider level because they want to tuck people in. Even Option Care in some of their markets has difficulty getting people into an ambulatory infusion suite because they're known as a home infusion company. So really working to leverage that outpatient ambulatory infusion center with the working population of people who might need IV antibiotics or somebody who works who has TPN who just once a week needs to come in for dressing change in labs.

JM: Thank you so much for joining us.

CA: That's the patient type that fits into what LUX already does, but can help turn a little bit into a more full-service provider.

JM: Perfect. Thank you so much for that. I'm just looking through a few additional agenda items that we had. They really emphasize that transplant and bleeding disorder therapies, they have some advantage there based on your experience maybe. Are these credible sources of differentiated growth for LUX or... Would it be difficult to maybe replicate some of that access and clinical expertise that they have in other areas? What would they maybe need to verify that they can really take opportunity in the transplant and bleeding disorder therapy market?

CA: Those are very, you know, niche markets that are generally localized to heavily metropolitan areas.

JM: Hello?

CA: Hello?

JM: Hello? Sorry, it seems like you dropped, yes?

CA: Well, I was fine. I don't know what happened.

JM: Oh, I apologize. I apologize. Yes, you were saying it just cut off in your initial comment on their presence in that market and you were saying maybe those are more for metropolitan areas and that's where it cut off.

CA: Okay, yeah, so those centers of excellence for bleeding disorders and for transplants take place in metropolitan areas. Now, there are patients obviously that come to those destination sites for that type of care and go back out to rural markets to receive their care. But that is where LUX Infusion has to look for where is our flag, our hub planted versus what type of nursing relationships do we have in those destination markets? And so really building a network

10/12/2026 at 06:03 AM UTC

and infrastructure of being able to not only deliver the medication, but have the clinical pathway that is desirable by those types of centers of excellence and being able to execute on the delivery of the nursing needed to be able to provide those therapies. And so it's really a pronged approach when you're looking at becoming a leader in those markets, you've got to cover all pieces and parts.

JM: And then they've also opened, I think, around 6 clinics in New Jersey and New York. Where do you see those additions being meaningful from a strategy perspective?

CA: Extremely important. That's the market density that I was talking about. You know, in order to be a player in this market, it is about footprint and even a perceived density, right? And in an infusion space, it is: can I have access to care within 1 hour of where that facility sits? And so providing these, what I call a hub and spoke approach. You know, a wheel, when you think about our ambulatory infusion suites, nobody should have to drive more than 1 hour to get to an ambulatory infusion suite or they're not going to come. And then within that, what is my home infusion space reach around that ambulatory infusion suite? Reach and creating a network of home infusion or nursing providers to be able to provide me an even greater reach from a home infusion perspective. That's the kind of strategy that wins is being able to increase the density where they currently are planted.

JM: Perfect. Thank you so much for that. And just lastly, I know we covered a lot of ground today. Anything else that maybe we haven't touched on that you think would be important for anyone doing their due diligence on LUX Infusion and maybe what else would we need to see over the next 12 to 24 months to become more confident that they can sustain or expand that center level EBITDA margins that we've discussed?

CA: I think just really making sure that your individual AIC chair utilization is where it needs to be. You know, 80% needs to be scheduled full 80% and then actual 70% butts in the seats; in order, that's even a driver. You need to make sure that your nurses inside those infusion suites are seeing 9 to 12 patients at a time. If their productivity is not that high, you're eating your EBITDA every time when you do that.

JM: Perfect. Thank you so much, Colleen. Really appreciate it and we'll definitely follow up as we do more work here. All right. I appreciate it. Thank you so much. Thank you. Bye-bye. Bye.

DISCLAIMER: The statements or opinions expressed today are those of the Advisor and not Guidepoint, who disclaims all liability for the content provided. The Advisor may not disclose material nonpublic or confidential information or any information that would cause the Advisor to breach any duty or obligations. Guidepoint is not a registered investment advisor and the information provided is not intended to constitute investment advice.

10/12/2026 at 06:03 AM UTC